Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

UC Irvine

Neither a doctor nor a teaching hospital

Research payments

$57,435

45 payments

Through program year 2025, UC Irvine is reported as receiving $57,435 in research payments, across 45 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $770 11
2024 Research $3,210 4
2023 Research $37,500 2
2022 Research $5,174 21
2021 Research $8,704 3
2020 Research $2,078 4

Breakdown

Who paid Research payments · program years 2020–2025
  1. Karyopharm Therapeutics Inc. $37,500 2 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $5,984 2 payments
  3. Telix Pharmaceuticals $3,000 1 payment
  4. Pfizer Inc. $2,720 1 payment
  5. Incyte Corporation $2,706 18 payments
  6. Dexcom, Inc. $2,239 4 payments
  7. Genentech, Inc. $2,229 2 payments
  8. Argenx US, Inc. $980 14 payments
  9. Amgen Inc. $77 1 payment
Studies the money was for Research payments · program years 2020–2025
  1. A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma $37,500 2 payments
  2. R591-Tx: 177Lu-Tlx591-203: Prostact Global: Trial $3,000 1 payment
  3. A Phase 3 Multinational Randomized Openlabel Three Parallelarm Study of Pf06801591 An Antipd1 Antibody in Combination With Bacillus Calmetteguerin BCG Induction With Or Without BCG Maintenance Versus BCG Induction and Maintenance in Participants With Highrisk Bcgnaive Nonmuscle Invasive Bladder Cancer $2,720 1 payment
  4. A Phase 2, Randomized, Double-Blind, Vehicle-Controlled, Study of the Efficacy and Safety of Ruxolitinib Cream in Participants With Lichen Sclerosus $2,706 18 payments
  5. An Adaptive Platform Trial to Reduce Mortality and Ventilator Requirements for Critically Ill Patients $2,229 2 payments
  6. Comparison of Dexcom G6 Continuous Glucose Monitoring System and Blood Glucose Levels in Adult Hemodialysis Patients With Diabetes $2,000 3 payments
  7. A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy $980 14 payments
  8. Comparison Study of Hypoglycemia in Pregnancy in Women With No Complications and Women With Diabetes $239 1 payment
  9. AMG 199 20180290 Container. $77 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record